Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron
Pharmaforum
Tue, 01/25/22 - 10:44 am
Tags:
COVID-19, Eli Lilly, Regeneron, antibodies, Omicron COVID-19 variant
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Thu, 01/20/22 - 11:00 am
Tags:
Regeneron, FDA, Libtayo, non-small cell lung cancer
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema
Fierce Pharma
Sun, 01/16/22 - 03:53 am
Tags:
Pfizer, Sanofi, Regeneron, FDA, Cibinqo, atopic dermatitis
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
Tags:
JPMHC 2022, Novartis, Leqvio, drug launches, Regeneron, Amgen, Sanofi
Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx
Endpoints
Fri, 01/7/22 - 10:36 am
Tags:
Regeneron, evinacumab, Ultragenyx
Leo puts target on Dupixent in US as FDA clears tralokinumab
Pharmaforum
Thu, 12/30/21 - 10:45 am
Tags:
Sanofi, Regeneron, Dupixent, tralokinumab, FDA
Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions
Fierce Pharma
Mon, 12/13/21 - 11:04 am
Tags:
Sanofi, Regeneron, Dupixent, eczema, pediatric
Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most
Stat
Wed, 12/8/21 - 11:45 pm
Tags:
Sanofi, Regeneron, asthma, pediatric, COVID-19, clinical trial diversity
November sees Sanofi-Regeneron dethroned after 6-month rule over top TV ad spender list
Fierce Pharma
Sun, 12/5/21 - 10:45 pm
Tags:
Sanofi, Regeneron, Dupixent, DTC advertising, television ads
Regeneron warns its antibody drug may be less potent versus omicron
BioPharma Dive
Tue, 11/30/21 - 10:38 am
Tags:
Regeneron, antibodies, COVID-19, Omicron COVID-19 variant
Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron
Fierce Pharma
Mon, 11/29/21 - 10:44 pm
Tags:
Amgen, Sanofi, Regeneron, patents, Supreme Court, Repatha
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Fierce Biotech
Wed, 11/24/21 - 10:15 am
Tags:
Pfizer, Regeneron, antisense, clinical trials, vupanorsen, dyslipidemia
Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron
Endpoints
Tue, 11/23/21 - 09:51 am
Tags:
Vaccibody, Nykode Therapeutics, Regeneron, biobucks, cancer, infectious disease
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
Motley Fool
Sat, 11/20/21 - 12:01 pm
Tags:
Regeneron, Roche, COVID-19, antibodies
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
BioSpace
Mon, 11/15/21 - 11:55 pm
Tags:
Merck, PCSK9 inhibitors, Amgen, Repatha, Esperion, Sanofi, Regeneron, Praluent
Regeneron COVID-19 antibody drug reduces infection risk 82% in clinical trial
Beckers Hospital Review
Mon, 11/8/21 - 11:03 am
Tags:
Regeneron, COVID-19, antibodies, clinical trials
How Regeneron's Covid Drug Lent Itself To A Big Third-Quarter Beat
Investors Business Daily
Thu, 11/4/21 - 10:41 am
Tags:
Regeneron, earnings, COVID-19
Sanofi, Regeneron gear up for new Dupixent filing after clearing second PhIII for eosinophilic esophagitis
Endpoints
Mon, 10/25/21 - 10:48 am
Tags:
Sanofi, Regeneron, Dupixent, eosinophilic esophagitis, clinical trials
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
Motley Fool
Fri, 10/22/21 - 12:18 pm
Tags:
Merck, COVID-19, molnupiravir, Regeneron, Eli Lilly, antibodies
Dupixent scores a first in rare skin disease prurigo nodularis
Pharmaforum
Fri, 10/22/21 - 11:22 am
Tags:
Sanofi, Regeneron, Dupixent, prurigo nodularis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.